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Abstract
Background: The presence of somatic mitochondrial DNA (mtDNA) mutations in cancer cells has been interpreted in
controversial ways, ranging from random neutral accumulation of mutations, to positive selection for high
pathogenicity, or conversely to purifying selection against high pathogenicity variants as occurs at the population level.
Methods: Here we evaluated the predicted pathogenicity of somatic mtDNA mutations described in cancer and
compare these to the distribution of variations observed in the global human population and all possible protein
variations that could occur in human mtDNA. We focus on oncocytic tumors, which are clearly associated with
mitochondrial dysfunction. The protein variant pathogenicity was predicted using two computational methods,
MutPred and SNPs&GO.
Results: The pathogenicity score of the somatic mtDNA variants were significantly higher in oncocytic tumors
compared to non-oncocytic tumors. Variations in subunits of Complex I of the electron transfer chain were
significantly more common in tumors with the oncocytic phenotype, while variations in Complex V subunits were
significantly more common in non-oncocytic tumors.
Conclusions: Our results show that the somatic mtDNA mutations reported over all tumors are indistinguishable
from a random selection from the set of all possible amino acid variations, and have therefore escaped the effects
of purifying selection that act strongly at the population level. We show that the pathogenicity of somatic mtDNA
mutations is a determining factor for the oncocytic phenotype. The opposite associations of the Complex I and
Complex V variants with the oncocytic and non-oncocytic tumors implies that low mitochondrial membrane
potential may play an important role in determining the oncocytic phenotype.
Background
Mitochondrial DNA (mtDNA) variations have been
implicated in many complex diseases, but the proof for
these associations has been hard to establish [1]. One
reason for the complexity is the extreme difficulty in
defining a precise phenotype where the influence of
mtDNA mutations can be clearly ascertained. Cancer is
a good example of a complex set of diseases that have
been related to mtDNA mutations [2]. Fortunately,
there is a phenotype in cancer that shows a clear-cut
mitochondrial involvement: the oncocytic tumor, also
designated as oncocytoma, oxyphilic tumor, Hürtle cell
tumor (in thyroid) and Warthin’s tumor (in salivary
glands). An oncocyte is a cell filled with mitochondria,
and hence displaying a grainy, eosinophilic appearance
and a swollen cytoplasm. This cellular phenotype can
also occur in normal parathyroid glands of the elderly,
in inflammatory autoimmune disorders as Hashimoto’s
* Correspondence: david.samuels@chgr.mc.vanderbilt.edu
3Center for Human Genetics Research, Department of Molecular Physiology
and Biophysics, Vanderbilt University Medical Center, Nashville, TN, USA
Full list of author information is available at the end of the article
Pereira et al. BMC Cancer 2012, 12:53
http://www.biomedcentral.com/1471-2407/12/53
© 2012 Pereira et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
thyroiditis, and in hyperplastic conditions as an adeno-
matous goiter displaying oncocytic transformation (see
review in [3]). Most of these oncocytomas, which prefer-
entially occur in the endocrine system and in some par-
enchymatous organs (very frequently in thyroid, kidney,
salivary glands and parathyroid), are usually benign
tumors displaying low invasiveness, although a few can
become malignant, especially in the thyroid, where the
phenotype may interfere with the intake of iodine-131
used for treatment [4,5]. Tumors can contain a mixture
of cells with and without the oncocytic phenotype. The
definition of a tumor as oncocytic depends on the frac-
tion of oncocytic cells within the tumor passing a rela-
tively high threshold. This threshold depends on the
organ involved, with typical levels being 75% in thyroid,
and with even stricter criteria in kidney and salivary
glands, since these are generally more homogeneous
neoplastic tissues [5].
Several studies have shown that oncocytic tumors
accumulate a higher frequency of mtDNA mutations
than non-oncocytic tumors, ranging from point substi-
tutions, to small insertion or deletions that can lead to
frameshifts or premature stop codons, and large-scale
deletions, namely the common 4977 bp deletion [6-10].
The point mutations occurring in oncocytic tumors in
most cases reach a homoplasmic level, and as expected
since they occupy a large fraction of the mitochondrial
genome, Complex I genes accumulate more mutations
in oncocytic tumors compared with the other complexes
having mtDNA-coded proteins (summarized in [11]),
and are thought to be responsible for the impairment of
oxidative phosphorylation (OXPHOS). These observa-
tions raise the question of whether these mutations con-
tribute to the oncocytic phenotype, an issue that must
be addressed in the general context of mtDNA diversity
in the global population and in cancer.
Studies on the human global population have shown
that mtDNA is under the effect of purifying selection,
resulting in a lower proportion of non-synonymous
mutations in the younger branches of the phylogenetic
tree [12-15]. We have recently added quantitative infor-
mation to clarify this selection [16], by using an objec-
tive measure of the depth of a node within a detailed
mtDNA tree combined with a predictor of pathogenicity
for non-synonymous mutations allowing one to distin-
guish between dangerous and almost-neutral non-
synonymous mutations. That study concluded that pro-
tein variants with high pathogenicity scores are statisti-
cally significantly rarer in the older branches of the tree,
a property common across the global population, repre-
sented by the macrohaplogroups L, M and N. We com-
pared the distribution of pathogenicity scores observed
on the human phylogenetic tree to the distribution of all
possible protein variations to define a measure of the
effect of selection on these protein variations, showing
that the effect of selection increases exponentially with
increasing pathogenicity score. This comparison estab-
lished that the pathogenicity scoring system used,
MutPred [17], could distinguish a fine gradation in
pathogenicity.
The literature on the role of mitochondrial DNA
mutations in cancer is in many cases contradictory.
Some authors have claimed that mtDNA somatic muta-
tions are accumulated in cancer cells due to a relaxation
of the negative selection acting at the population level,
thus consistent with neutrality [18]. Some mathematical
models taking into account several parameters (as
mtDNA point mutation fractions in a variety of human
tissues) [19] showed that the homoplasy of the cancer
somatic mtDNA mutations can be explained by random
processes of drift, without the need to invoke positive
selection for these mutations. However, other authors
[20] have argued that the available data support strong
selection against detrimental mtDNA mutations in
tumor cells, so that intact mitochondria are required for
successful tumorigenesis. Zhidkov et al. [21] analyzed
two datasets of somatic cancer mutations typed by the
high throughput mitochondrial sequencing array (Mito-
Chip) concluding that the patterns of mutation in
tumors are similar to the ones that occur in human evo-
lution, so that both are shaped by similar selective con-
strains. These authors saw that somatic cancer
mutations match the ones occurring in deep branches
of the tree. Palanichamy and Zhang [22] showed that
caution should be applied to the interpretation of data
from MitoChip studies, as the application of phyloge-
netic quality control criteria led to the identification of
many sample mix-ups; including in the dataset [23]
which constituted 83 of the 98 samples analyzed in [21],
where at least five samples had leucocytes belonging to
one haplogroup and tumor to a clearly different hap-
logroup (sometimes as far apart as African from Eura-
sian haplogroups), clearly the result of sample mix-ups.
Research on the role of mtDNA mutations in cancer
has a long history filled with controversy; however, none
of these works dealing with selection of the somatic can-
cer mtDNA mutations addressed the particular pheno-
type of oncocytic tumors, which is so clearly associated
with mitochondrial dysfunction. To focus the point we
consider the question of whether the predicted patho-
genicity of somatic mtDNA mutations is higher in onco-
cytic tumors than in non-oncocytic tumors.
Methods
Literature search
The MedLine search was performed by using the
queries “mtDNA AND cancer”, “mtDNA AND oncocy-
tic”, “mtDNA AND Hurtle”, “mtDNA AND oxyphilic”
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and “mtDNA AND Warthin”. The search was per-
formed in March 2011. For oncocytic and non-oncocytic
datasets, we reviewed each publication and only used
studies providing the complete mtDNA sequences,
deposited in public databases, and obtained by Sanger
sequencing [6,7,9]. These summed up to 101 oncocytic
(16 hyperplastic thyroid nodules, 7 follicular thyroid
adenomas, 22 thyroid carcinomas, 5 breast carcinomas,
9 renal oncocytomas, 25 pituitary adenomas, 16 head-
and-neck tumors and 1 nasopharinx tumor) and 86
non-oncocytic (6 hyperplastic thyroid nodules, 3 follicu-
lar thyroid adenomas, 12 thyroid carcinomas, 15 breast
carcinomas, 16 gliomas, 5 high-grade clear cell renal
carcinomas, 20 pituitary adenomas and 9 head-and-neck
tumors) samples. Data for the mtDNA variants reported
in oncocytic tumors is given in Additional file 1 and
data for the non-oncocytic tumors is given in Additional
File 2.
For comparison to the cancers explicitly classified as
oncocytic or non-oncocytic we also considered a set of
mtDNA somatic mutations in general cancers, where
there was no indication of a mitochondrial phenotype
and for most of which there was no mtDNA sequence
available for phylogenetic quality control [24-47]. For
these studies we only included results from sequences
obtained by Sanger sequencing, the same methodology
applied in the oncocytic and non-oncocytic datasets.
Data for mtDNA variants in these cancers is given in
Additional file 3.
Phylogenetic quality control
We used phylogenetic criteria [48-50] to apply a quality
control to somatic mutations, as problems of sample
mixing and poor quality of the material used have led to
many artifacts in previous cancer mtDNA datasets
[51,52]. The purpose of this focus on quality control is
to assemble a dataset with both clean genotyping and
phenotyping. Unfortunately, we could perform this
check only in the oncocytic/non-oncocytic datasets, as
full mtDNA sequence data was often missing in the
other cancer studies. For this reason, the results for the
other cancer class should be interpreted carefully, as
some described somatic cancer mutations in this list
might possibly have resulted from sample mix-up or
might contain editing or sequencing errors. In the
absence of the full sequences, we could not double-
check this dataset for those potential errors. The phylo-
genetic tree used in this quality control analysis is given
in Additional file 4.
Sequences from Gasparre et al. [6] were downloaded
from GenBank in FASTA format and transformed in a
list of polymorphisms by using the computer tool
mtDNA-GeneSyn [48]. Sequences from Gasparre et al.
[7] and Porcelli et al. [9] were extracted in the format of
a list of polymorphisms from the public database
HmtDB (http://www.hmtdb.uniba.it). We then used the
online tool Haplogrep [50] to check affiliation of the
samples into haplogroups. This tool is kept updated
relative to the most recent haplogroup classifications
based on complete mtDNA sequences and has the
advantages of indicating which haplogroup-defining
mutations would be expected in the sample and that
could have been missed due to editing errors or real
back mutations.
Some individuals in this data set miss polymorph-
isms that are haplogroup defining, especially in hap-
logroups J, T, U and I. The most problematic case is
sample PA13 (PA_EU_IT_0112 in database HmtDB),
which displays defining polymorphisms of haplogroups
U1a1 and J, being most probably a mix-up of
sequences from two individuals. Some of the few miss-
ing polymorphisms observed in those individuals can
be back-mutations, but there were some only observed
in the cancer tissue and not in the normal tissue,
which the authors interpreted to be related with can-
cer; here we interpreted these last as not relevant for
the tumor, being really missed mutations or back-
mutations in the normal tissue. For these quality con-
trol reasons, the following mutations were discarded
from the analysis: A8836G in samples HCT26 and
HCT44 [6] because it is N1b haplogroup defining;
T15674C in sample HCT6 [6] for being R0a2’3 hap-
logroup defining; A13973T in BRCA9 [6] for being
T2c1a haplogroup defining; A12961G in TC6 [6] for
being I5a1 haplogroup defining; G13889A in HNT10
[9] for being H4a1b haplogroup defining.
We also detected other inconsistencies between tables
reported in papers and sequences deposited in the
online databases. Mutation G10537A in sample HCT23
in Table 1 of Gasparre et al. [6] should be G10573A (as
in GenBank Accession Number EF660990) and G4063A
in sample Oncocytoma 6 in Table 1 of Gasparre et al.
[7] should be G4036A (as in sample PA_XX_XX_0006
in the database HmtDB). The following mutations
referred in papers are missing in the sequences depos-
ited, but were maintained in the analyses here: T4016G
in sample G5, Table 2 of Gasparre et al. [6] (EF660957
and PA_EU_IT_0045); G4831A in sample OPA11 in
Porcelli et al. [9] (PA_EU_IT_0136).
Somatic variants analyzed
In the data from the oncocytic and non-oncocytic
tumors very few mutations were described in the tRNA
and rRNA genes. There were three somatic variants in
tRNA genes (one in MT-TT [10], and another in MT-
TW and in MT-TI [9]) and two in rRNA genes (one in
MT-RNR2 [10] and one in MT-RNR1 [7]). These small
sample sizes do not allow a reliable application of
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statistical tests for the tRNA and rRNA genes therefore
our analysis focused on the protein coding genes.
Pathogenicity score
We aimed to predict the pathogenicity of non-synon-
ymous mutations accumulated in oncocytic, non-onco-
cytic and other cancers, compared with the distribution
of variations observed in the global human population
and all possible protein variations that could occur in
human mtDNA (through single nucleotide variations
from the standard reference sequence rCRS). The
MutPred score was determined in the cancer datasets as
described in reference [16]. Basically, the MutPred score
[17] is determined by a set of features reflecting protein
structure and its dynamics, the presence of functional
residues, biases of amino acid sequence, and evolution-
ary conservation at the substitution site and in its neigh-
borhood. The software was trained as a random forest
classification model to discriminate between disease-
associated amino acid substitutions from the Human
Gene Mutation Database and putatively neutral poly-
morphisms from Swiss-Prot.
We also used three other datasets of pathogenicity
scores for nonsynonymous mtDNA variations, published
previously as supplemental files in [16]. The dataset
denoted as “All Possible Variants” contains pathogeni-
city scores for all 24,206 amino acid variants that can be
generated by a single nucleotide change from the stan-
dard human mtDNA reference sequence, the rCRS [53].
The dataset denoted by “Population Variants” contained
pathogenicity scores for the 2,227 nonsynonymous var-
iants recorded in the global human mtDNA phyloge-
netic tree covering the L, M and N macrohaplogrops.
The dataset denoted as “OMIM Pathogenic Variants”
contained the pathogenicity scores for the 75 reported
pathogenic mtDNA variants listed in the Online Mende-
lian Inheritance in Man (OMIM) database as of Decem-
ber 2010. This OMIM dataset was limited to reported
single amino acid changes.
For comparison purposes, we estimated pathogenicity
scores with another algorithm called SNPs&GO [54].
Pathogenicity scores calculated by both methods are
included in Additional files: Table S1-Table S3. The
pathogenicity scores from both methods were compared
by nonparameteric Wilcoxon rank sum test.
Results
The complete lists of non-silent mtDNA mutations in
oncocytic, non-oncocytic and other tumors (which we
refer to as “general cancer”) used in this work are
reported in Additional files: Table S1-Table S3 respec-
tively. The general cancer dataset are from papers in
which no mention is made of either oncocytic or non-
oncocytic phenotype, so these tumors cannot be
classified into either of the first two categories. The
total data sum up to 67 mutations (40 of which lead to
frameshifts or premature stop codons) in oncocytic
tumors, 14 mutations (including 3 frameshifts or prema-
ture stop codons) in non-oncocytic tumors and 107
mutations (including 16 frameshifts or premature stop
codons) in other cancers. The proportion of disruptive
variations (the frameshifts and premature stop codons)
is 60% in oncocytic tumors and only 21% in the non-
oncocytic tumors, constituting a significant difference (p
= 0.016) by a Fisher’s exact test. This testifies to a signif-
icant accumulation of severe mutations in oncocytic
tumors when compared with non-oncocytic tumors, as
has been previously reported [6,7,9].
For each of the 13 mtDNA encoded protein genes we
compared the number of non-silent variations (nonsy-
nonymous, indels and premature stop codons) found in
the oncocytic tumors to the number in the general can-
cer tumors. With only 14 non-silent variations in the
non-oncocytic tumors, there was not sufficient data to
break those data down by gene. For two genes there
were highly significant differences in the variation fre-
quencies in the oncocytic and general cancer categories.
The occurrence of non-silent mutations in the MT-ND1
gene was 4.3 times higher in the oncocytic tumors than
in the general cancer tumors (p value = 0.0006 by two-
tailed Fisher’s exact test). Conversely, the MT-CO3 gene
had 0/67 non-silent variants in the oncocytic tumors
but 12/107 in the general cancers (p value = 0.004).
Even when correcting for 13 tests these two tests remain
significant at a threshold p value of 0.05/13 = 0.004. The
other eleven genes had no significant difference between
the oncocytic tumors and general cancers. These statisti-
cally significant values by comparing oncocytic and gen-
eral cancers strengthen the observation made previously
without statistical testing [11] (where only oncocytic
mutations and the ratio per gene (normalized for the
gene size) were analyzed) that mutations accumulate
preferentially in the MT-ND1 gene. The authors in that
work also reported that MT-CO1 and MT-ATP8 genes
seemed to be protected, a characteristic common to all
other complex IV and V genes when information about
the potential pathogenicity of the mutations was taken
into consideration. This result is consistent with our
independent observation of a significant lower mutation
frequency in MT-CO3 gene in oncocytic tumors. Our
results significantly extend these earlier observations by
using a comparison of mutations reported in oncocytic
tumors to mutations reported in general cancers and by
showing that these differences are highly statistically
significant.
The 13 proteins encoded by mtDNA are core subunits
for four of the five protein complexes that make up the
electron transfer chain (ETC). If we analyze the
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distribution of the non-silent variations by ETC com-
plex, then there is enough data in the non-oncocytic
tumors for significant results (Table 1). With 12 tests,
the adjusted target significance level is 0.05/12 = 0.004.
Consistent with the analysis in the previous paragraph,
non-silent variants in the Complex I genes were far
more likely to be found in the oncocytic tumors than in
the non-oncocytic tumors. Conversely, non-silent varia-
tions were less likely in the Complex IV genes in onco-
cytic tumors compared to non-oncocytic tumors. There
also was a significant decrease in the non-silent variants
in Complex V in the oncocytic tumors compared to the
non-oncocytic tumors. Only Complex III, which is
represented by just a single mtDNA encoded gene, did
not have a significant difference between the oncocytic
and non-oncocytic tumors. The comparison of the
oncocytic tumor variants with the general cancer var-
iants gives the same pattern of significant differences,
with the interesting exception of Complex V, which has
no significant difference in this comparison. Finally, in
the comparison between the non-oncocytic tumor var-
iants and the general cancer variants, there was a nom-
inally significant difference only in the Complex V genes
(though this was not significant after correction for mul-
tiple testing). The picture that results from these com-
parisons is that non-silent mtDNA mutations in
Complex I are more likely to be found in the oncocytic
tumors, while non-silent variations in Complex V are
more likely in the non-oncocytic tumors.
While the pathogenicity of variations causing prema-
ture stop codons or frameshifts is obvious, the patho-
genicity of non-synonymous variants may be highly
variable, ranging from benign to highly pathogenic var-
iations. Several methods of predicting the pathogenicity
of nonsynonymous variations exist [55]. For the
reported pathogenic variations resulting in a single
amino acid change, we calculated predicted pathogeni-
city scores using the MutPred software [16,17]. The
pathogenicity score in this method ranges from 0 to 1,
with higher values indicating more severe pathogenicity.
The nonsynonymous variations in the oncocytic tumors
(Figure 1) have significantly higher median pathogenicity
scores than the variations in non-oncocytic tumors (p =
0.016, by Wilcoxon rank sum test). The oncocytic
tumors are also significantly higher in median patho-
genicity score (p = 3 × 10-4) than the variations reported
in general cancers. The difference between the patho-
genicity scores in the non-oncocytic tumors and the
general cancers is not significant, and the distribution of
scores in these two categories, as shown in the box
plots (Figure 1), is quite similar.
For a wider comparison we also considered three
other categories of mtDNA variations; all reported
pathogenic mtDNA protein variations (compiled from
OMIM), all possible variations in the mtDNA encoded
proteins defined by single nucleotide variations from the
reference sequence rCRS [53], and all observed mtDNA-
encoded protein variations reported in large human
phylogenetic trees (representing the general population
variants). These values were all reported in [16] and
detailed explanations of their definition are given there.
Briefly, we take set of OMIM variations as a set of non-
synonymous mtDNA variations with some level of proof
of pathogenicity. The set of all possible variations in the
mtDNA encoded proteins contains all 24206 amino acid
changes that can be generated by a single nucleotide
change from the rCRS. This is meant to represent the
set of all possible random changes. The final group is
the set of all observed non-synonymous mtDNA var-
iants collected from human phylogenetic trees (further
details of the trees are given in [16]). This group repre-
sents the population level variants in these proteins.
Table 1 Statistics for counts of non-silent mtDNA variants organized by electron transfer chain complex.
Oncocytic vs Non-oncocytic Oncocytic vs General Cancer Non-oncocytic vs General Cancer
Complex I,
p-value
0.003 0.00002 0.77
Complex I,
OR [CI]
7.4 [2 - 27] 5.6 [2.4 - 13] NS
Complex III,
p-value
0.58 0.44 0.23
Complex III, OR [CI] NS NS NS
Complex IV,
p-value
0.034 0.0004 1
Complex IV, OR [CI] 0.11 [0.02 - 0.75] 0.1 [0.02 - 0.4] NS
Complex V,
p-value
0.003 0.16 0.03
Complex V,
OR [CI]
0.04 [0.004 - 0.37] NS 5 [1.3 - 19]
NS = not significant
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Figure 2 presents the distributions of the predicted
pathogenicity scores for each of these categories, com-
pared with the oncocytic and non-oncocytic tumor
mtDNA variations. The median pathogenicity scores for
the oncocytic tumors are significantly higher than the
scores for all these categories of variations (p = 0.007
for oncocytic vs OMIM pathogenic variants; p = 1 × 10-
5 for oncocytic vs all possible variants; p = 6 × 10-14 for
oncocytic vs general population variants). The fact that
the oncocytic tumor variants have significantly higher
pathogenicity scores than the reported pathogenic
mtDNA variation in OMIM emphasizes the point that
the variants reported in these tumors should be consid-
ered highly pathogenic. If the somatic mtDNA variants
are created randomly along the mitochondrial genome,
then they should, at least approximately, be random
samplings from the set of all possible variants. The fact
that the oncocytic mtDNA variants have significantly
higher pathogenicity scores than the set of all possible
variants means that the oncocytic mtDNA variants are
even worse than would be expected from random
changes to the mtDNA.
The non-oncocytic tumor variants were only nomin-
ally significantly different from the general population
variants (p = 0.026). This p-value is not low enough to
survive multiple testing corrections for five tests. Con-
versely, the non-oncocytic tumor variations are not sig-
nificantly different from the set of all possible variants
(p = 0.6), though this lack of significance must be inter-
preted with care due to the small amount of non-onco-
cytic variant data. However it is clear that both the non-
oncocytic and oncocytic mtDNA variations have for the
most part escaped the purifying selection that causes the
mean pathogenicity score in the population variants to
be so small (Figure 2). The median pathogenicity score
for the oncocytic variants is significantly higher than the
median score for all possible variants while the median
score for the non-oncocytic variants is smaller than that
for all possible variants (though that difference does not
reach significance). A reasonable interpretation of this
pattern is that the somatic variations arise as a random
sampling from all possible variations (at least approxi-
mately), and that those tumor cells that contain high
levels of mtDNA variants with very high pathogenicity
scores tend to develop the oncocytic phenotype, while
those tumor cells with lower pathogenicity scores tend
to maintain the non-oncocytic phenotype.
MutPred is only one of many available methods for
predicting the pathogenicity of nonsynonymous variants.
A recent test [55] of several of these methods deter-
mined that the overall best performing methods were
MutPred and SNPs&GO [54]. To test whether these
results generalized to other pathogenicity scoring sys-
tems, we repeated the analysis using the SNPs&GO soft-
ware. SNPs&GO classifies variants into “Neutral” or
“Disease” categories, along with a reliability index ran-
ging from 0 to 10, with high values denoting more reli-
able predictions. In these datasets few variants had
reliability scores of 7 or higher, so we chose to only
include variants with SNPs&GO reliability scores ≥ 5 in
order to have a reasonably high reliability score while
also having enough data to analyze. The results reported
below were significant for all choices of reliability score
cut-off from 0 (using all data) to 6, and there was not
enough data with a reliability score above 6 to warrant
testing. Our first test was to see whether the MutPred
scores and SNPs&GO categories for the variants in this
study were consistent. In Figure 3, we compare the
MutPred pathogenicity scores for variants in the
SNPs&GO “Disease” category to the MutPred scores for
variants in the SNPs&GO “Neutral” category. The com-
parison is very highly significant (p-value = 4 × 10-8 by
nonparametric Wilcoxon rank sum test), proving that
the pathogenicity assessment of these two different
methods has good agreement (i.e. variants classified by
SNPs&GO as “Disease” also had significantly higher
MutPred pathogenicity scores on average).
Finally, we used the SNPs&GO pathogenicity analysis
to compare the nonsynonymous mtDNA variations in
the oncocytic, non-oncocytic and general cancer tumors.
Of the 11 nonsynonymous variants in the non-oncocytic
tumors, only two had SNPs&GO reliability indices ≥ 5,
Figure 1 Pathogenicity scores of mtDNA variants in oncocytic,
non-oncocytic, and general cancers. Each point represents a
somatic mtDNA mutation resulting in a single amino acid change.
In each category, individual data points are given to the left, and
the statistics of the distribution are given in the bar chart to the
right (square = mean, line = median, box = second and third
quartiles, asterisk = max and min data values). P values are from
nonparametric Wilcoxon rank sum tests. With three tests, the
significance threshold is 0.05/3 = 0.017
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so there was not enough data to analyze that category
using this method. In the oncocytic tumors, 7/8 nonsy-
nonymous mtDNA variants were reliably classified by
SNPs&GO as “Disease”, while in the general cancer
tumors only 12/46 were reliably classified as “Disease”, a
highly significant difference (p-value = 0.0018 by Fisher’s
exact test). Thus, the SNPs&GO analysis agrees with the
MutPred analysis. Both tests conclude that mtDNA var-
iations reported in oncocytic tumors have higher patho-
genicity than the mtDNA variants reported in general
cancers.
Discussion
Oncocytic cells are not only found in cancer. They also
have been reported in normal aging tissue, in inflamma-
tory autoimmune disorders as the Hashimoto’s thyroidi-
tis, and in hyperplastic conditions as adenomatous
goiter displaying oncocytic transformation (reviewed in
[3]). There are currently no genetic data available for
these tissues, and the only indirect evidence results from
an immunohistochemistry study [56], which describes
that oxyphil cells from normal parathyroid gland
Figure 2 Comparison to pathogenic mtDNA variants, all possible variants and population level variants. The distribution of
pathogenicity scores of mtDNA variations in oncocytic tumors (red) and non-oncytic and general cancer (both blue) are compared to reported
mtDNA pathogenic variations, all possible variations, and normal population variations (all gray). For details on the final three categories, see the
text and [16]. With five tests, the corrected significance threshold is 0.01
Figure 3 Comparison of the pathogenicity assessment of the
SNPs&GO method and the MutPred method. All mtDNA variants
in this study were assessed together. The bar plots represent the
statistics of each data set as in Figure 1
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frequently present respiratory defects. It would be very
interesting to test mtDNA variants observed in non-can-
cerous oncocytic cells found for instance in elderly para-
thyroid glands, in inflammatory autoimmune disorders
and in hyperplastic conditions. This would determine if
the oncocytic phenotype observed in these non-cancer
tissues could also be due to highly pathogenic mtDNA
mutations, as we have shown that it is in oncocytic
tumor cells. Also, the comparison of the pathogenicity
scores for mtDNA variants between primary and sec-
ondary oncocytic carcinomas (where the hit for hyper-
plasia of mitochondria occurs prior or after the hit for
tumorigenesis, respectively [57]) could add valuable
information to this issue. An interesting case has been
described of a disruptive frameshift mtDNA mutation
affecting MT-ND5 that was inherited at low hetero-
plasmy in the family of a patient where it became
homoplasmic in a tumor of this individual [58]. That
tumor showed an oncocytic phenotype, as we would
expect from this analysis. In another study [6], the
authors reported a peculiar case of a patient that pre-
sented three thyroid tumor nodules, of which only one
displayed the oncocytic phenotype and the same non-
sense mutation in MT-ND5, suggesting that this muta-
tion could be responsible for the mitochondrial
hyperplasia and hence for the Hürthle cell transforma-
tion in this case. Based on these results, we would
expect that individuals carrying inherited proven patho-
genic mutations, as in these cases, would be predisposed
to developing the oncocytic phenotype of tumors, with
the possible exception of individuals carrying pathogenic
complex V protein variants who may be predisposed to
the non-oncocytic tumor phenotype.
Mitochondrial hyperplasia, as occurs in the oncocytic
phenotype, is generally considered to be a compensatory
effect (reviewed in [11]) triggered in response to a retro-
grade signaling from dysfunctional mitochondria to the
nucleus. The nuclear response activates the mitochon-
drial biogenesis pathways in order to overcome the
defective OXPHOS function. In this view, mtDNA
mutations have a causative role in the activation of the
mitochondrial hyperplasia. Some authors [59,60] have
argued that the selection of the phenotype has been dri-
ven by the micro-environment of the epithelial-cancers
(where the oncocytic phenotypes are observed). Most of
these cells are far away from the blood vessels in the
early phases of the carcinoma, and are thus periodically
under hypoxia, which will select for cells with up-regu-
lated glucose consumption, assuming a glycolytic pheno-
type. These authors stress that the phenotype, not the
genotype, is evolutionary selected, so that multiple
mechanisms for up-regulating glucose consumption can
be observed. In this case, the oncocytic phenotype could
be one of several such mechanisms increasing glycolysis,
but here the trigger could be environmental and not ori-
ginated by the mtDNA mutations. Interestingly, when
primary cultures from two thyroid tumors were estab-
lished [6], each with a disruptive mtDNA mutation,
both the mutations and the oncocytic phenotype were
lost during culture. The authors suggested that under
the culture conditions used the mtDNA mutations were
under negative selection. Therefore, it seems that the in
vivo environment of the cancer, such as hypoxia, is
mandatory for the maintenance of the disruptive muta-
tions and oncocytic phenotype.
Does this “positive selection” of the phenotype mean
that those tumor cells with the high pathogenicity scores
have had a better chance of survival? A commonly
accepted explanation for the growth advantage in
tumors relates to survival due to prevention of apopto-
sis, in which mitochondria play a main role. It has been
shown that impairment of OXPHOS may protect cells
from apoptosis [61], but it remains to be clearly shown
if this happens in oncocytic tumors [4,11]. A very inter-
esting issue is that despite the high pathogenicity of the
mtDNA mutations, the impairment of OXPHOS and
the oncocytic phenotype, usually (except for thyroid)
indicates a tumor with low proliferative turn-over and is
thus associated, in most instances, to benign neoplasms
or tumors of low malignancy [5]. The idea of “adaptive
landscapes” [59,60] tries to explain the acquisition of the
properties of malignancy and invasion by sequential
steps. Some authors have already investigated the levels
of the hypoxia inducible factor-1a (HIF1a), which is
activated by prolyl hydroxylases controlled by Krebs
cycle metabolites (succinate and fumarate). In the onco-
cytic cell line XTC.UC1 a chronic destabilization of
HIF1a was observed [9]. HIF1a is the main inducer of
the vascular endothelial growth factor (VEGF), which
regulates the generation of novel vasculature in the
hypoxia environment. It seems then possible that HIF1a
destabilization in oncocytic cells should occur after the
homoplasmic shift of the mtDNA mutation and before
neovascularization in tumor progression [9].
Conclusions
When analyzing somatic mtDNA cancer mutations
checked carefully for quality control based on phyloge-
netic criteria, our results showed that these variants
seem to be accumulating at random from the set of all
possible protein variations. This escape from the effects
of purifying selection acting at the population level is
most probably due to the protection of these cells from
apoptosis. Based on these data it is reasonable to make
the inference that the severity of the pathogenicity score
of the mtDNA variants in the tumor is a major factor
determining whether the tumor develops an oncocytic
or a non-oncocytic phenotype. Furthermore, we
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confirmed that non-silent Complex I variants are found
more often in the oncocytic phenotype (an observation
that we now support by statistical test) while we also
discovered that non-silent Complex V variants are more
common in the non-oncocytic phenotype. Since the
activity of Complex I raises the mitochondrial mem-
brane potential and Complex V lowers the membrane
potential, this argues for an important role of the mem-
brane potential in the determination of the oncocytic or
non-oncocytic phenotype.
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